Galectin Therapeutics Inc
GALT- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001133416
No open-market purchases or sales by Galectin Therapeutics Inc insiders were filed in the last 90 days; 104 institutions reported holding it in 13F filings for Q3 2026, worth $62.2M in total; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Nov 17, 2026, 2:19 AM ET
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 31, 2026 | Mar 31, 2025 | Mar 29, 2024 | Mar 30, 2023 | Mar 31, 2022 |
| Operating expenses | $20.1M | $42.4M | $38.1M | $38.4M | $30.2M |
| Research and development | $14.3M | $36.6M | $32.1M | $31.7M | $23.8M |
| Selling, general and administrative | $5.79M | $5.86M | $5.94M | $6.62M | $6.36M |
| Operating income | -$20.1M | -$42.4M | -$38.1M | -$38.4M | -$30.2M |
| Interest expense | – | – | $2.79M | $1.03M | $489.0K |
| Income tax | $0 | – | – | – | – |
| Net income | -$30.8M | -$47.0M | -$41.1M | -$38.8M | -$30.5M |
| EPS, basic | $-0.48 | $-0.76 | $-0.74 | $-0.65 | $-0.52 |
| EPS, diluted | $-0.48 | $-0.76 | $-0.74 | $-0.65 | $-0.52 |
| Weighted shares, basic | 63.9M | 62.3M | 60.2M | 59.4M | 58.5M |
| Weighted shares, diluted | 63.9M | 62.3M | 60.2M | 59.4M | 58.5M |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025! | FY2024! | FY2023! | FY2022! | FY2021! |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 31, 2026 | Mar 31, 2025 | Mar 29, 2024 | Mar 30, 2023 | Mar 31, 2022 |
| Cash and equivalents | $17.7M | $15.1M | $25.7M | $18.6M | $39.6M |
| Total current assets | $19.4M | $17.3M | $27.7M | $20.6M | $41.8M |
| Property, plant and equipment | $0 | $0 | $0 | $0 | $0 |
| Total assets | $19.5M | $17.5M | $28.2M | $21.3M | $41.8M |
| Accounts payable | $3.25M | $5.66M | $6.43M | $3.89M | $1.80M |
| Total current liabilities | $8.03M | $35.4M | $15.7M | $13.0M | $9.03M |
| Total liabilities | $145.7M | $120.6M | $88.4M | $53.5M | $39.2M |
| Shareholders' equity | -$127.9M | -$104.8M | -$62.0M | -$33.9M | $893.0K |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 31, 2026 | Mar 31, 2025 | Mar 29, 2024 | Mar 30, 2023 | Mar 31, 2022 |
| Operating cash flow | -$23.9M | -$41.8M | -$33.0M | -$31.1M | -$24.3M |
| Depreciation and amortization | – | $0 | $0 | $0 | $0 |
| Stock-based compensation | $1.66M | $2.45M | $2.26M | $2.87M | $2.08M |
| Investing cash flow | $0 | $0 | $0 | $0 | $0 |
| Financing cash flow | $26.5M | $31.2M | $40.0M | $10.0M | $36.8M |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Nov 6, 2026 | 100.9M | +56.5% | SEC |
| Aug 6, 2026 | 100.8M | +57.4% | SEC |
| May 8, 2026 | 65.9M | +4.1% | SEC |
| Mar 2, 2026 | 65.8M | +4.2% | SEC |
| Nov 7, 2025 | 64.5M | +2.7% | SEC |
| Aug 7, 2025 | 64.1M | +2.9% | SEC |
| May 7, 2025 | 63.3M | +1.8% | SEC |
| Mar 3, 2025 | 63.2M | +2.1% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
- A column marked ! failed an accounting identity (gross profit = revenue − cost of revenue, or assets = liabilities + equity, within 1%). Its numbers are shown as filed.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.